Literature DB >> 23605781

The treatment outcome for adult patients with Ewing's sarcoma.

Kristen N Ganjoo1, Shreyaskumar Patel.   

Abstract

Ewing's sarcoma is the second most common bone malignancy in children, but is extremely rare in adults. The outcome of patients with localized disease has improved over the past decades due to better combination chemotherapies, and better methods of local control. Unfortunately, patients with metastatic disease have a very poor outcome with current antineoplastic therapies. In this article, we will review the primary treatment for adult patients with Ewing's sarcoma, both for localized and metastatic disease. The prognostic factors in adult patients with EWS will also be reviewed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605781     DOI: 10.1007/s11912-013-0317-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  27 in total

1.  Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.

Authors:  G Bacci; S Ferrari; F Bertoni; S Rimondini; A Longhi; P Bacchini; C Forni; M Manfrini; D Donati; P Picci
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years.

Authors:  Gaetano Bacci; Alba Balladelli; Cristiana Forni; Stefano Ferrari; Alessandra Longhi; Patrizia Bacchini; Marco Alberghini; Nicola Fabbri; Mariaserena Benassi; Antonio Briccoli; Piero Picci
Journal:  Cancer       Date:  2007-02-15       Impact factor: 6.860

3.  Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children?

Authors:  M W Verrill; I R Judson; C L Harmer; C Fisher; J M Thomas; E Wiltshaw
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

4.  Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

Authors:  Christine Juergens; Claire Weston; Ian Lewis; Jeremy Whelan; Michael Paulussen; Odile Oberlin; Jean Michon; Andreas Zoubek; Herbert Juergens; Alan Craft
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

5.  Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience.

Authors:  P Rosito; A F Mancini; R Rondelli; M E Abate; A Pession; L Bedei; G Bacci; P Picci; M Mercuri; P Ruggieri; G Frezza; M Campanacci; G Paolucci
Journal:  Cancer       Date:  1999-08-01       Impact factor: 6.860

6.  Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.

Authors:  E H Baldini; G D Demetri; C D Fletcher; J Foran; K C Marcus; S Singer
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

7.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors:  Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

8.  Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival?

Authors:  Robert C G Martin; Murray F Brennan
Journal:  Arch Surg       Date:  2003-03

9.  Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints.

Authors:  J Zucman; O Delattre; C Desmaze; B Plougastel; I Joubert; T Melot; M Peter; P De Jong; G Rouleau; A Aurias
Journal:  Genes Chromosomes Cancer       Date:  1992-11       Impact factor: 5.006

10.  Ewing sarcoma: its course and treatment in 50 adult patients.

Authors:  J G Sinkovics; C Plager; A G Ayala; R D Lindberg; M L Samuels
Journal:  Oncology       Date:  1980       Impact factor: 2.935

View more
  4 in total

1.  Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management.

Authors:  Christoph Minichsdorfer; Oskar Steinbrecher; Marita KÖlz; Maximilian Schmid; Markus Raderer; Thomas Brodowicz; Wolfgang Lamm
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma.

Authors:  Annelies Requilé; Paul M Clement; Oliver E Bechter; Herlinde Dumez; Annelies Verbiest; Raf Sciot; Daphne Hompes; Friedl Sinnaeve; Erik Van Limbergen; Patrick Schöffski
Journal:  Sarcoma       Date:  2017-12-28

3.  Ewing's Sarcoma as a Second Malignancy in Long-Term Survivors of Childhood Hematologic Malignancies.

Authors:  Fabian Wolpert; Michael A Grotzer; Felix Niggli; Dieter Zimmermann; Elisabeth Rushing; Beata Bode-Lesniewska
Journal:  Sarcoma       Date:  2016-07-25

4.  Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.

Authors:  Jianjun Zhang; Yujing Huang; Yuanjue Sun; Aina He; Yan Zhou; Haiyan Hu; Yang Yao; Zan Shen
Journal:  BMC Cancer       Date:  2019-12-02       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.